- Home
- TJX vs AMGN Comparison
TJX vs AMGN Comparison
Compare TJX & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJX | AMGN |
|---|---|---|
| Founded | 1962 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.6B | 224.2B |
| IPO Year | 1994 | 2002 |
Fundamental Metrics
Financial Performance| Metric | TJX | AMGN |
|---|---|---|
| Price | $144.26 | $438.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 34 |
| Target Price | $170.80 | ★ $394.98 |
| AVG Volume (30 Days) | ★ 6.3M | 2.6M |
| Earning Date | 11-18-2026 | 11-03-2026 |
| Dividend Yield | 1.33% | ★ 2.32% |
| EPS Growth | 14.32 | ★ 88.23 |
| EPS | 2.55 | ★ 7.71 |
| Revenue | ★ $29,078,407,000.00 | $25,424,000,000.00 |
| Revenue This Year | $6.06 | $6.05 |
| Revenue Next Year | $6.26 | $3.64 |
| P/E Ratio | $56.67 | ★ $56.32 |
| Revenue Growth | 6.04 | ★ 8.83 |
| 52 Week Low | $122.81 | $288.26 |
| 52 Week High | $170.00 | $447.03 |
Technical Indicators
Market Signals| Indicator | TJX | AMGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.32 | 63.72 |
| Support Level | $122.81 | $338.03 |
| Resistance Level | $162.20 | $446.42 |
| Average True Range (ATR) | 2.67 | 9.35 |
| MACD | 1.62 | 2.60 |
| Stochastic Oscillator | 88.47 | 83.52 |
Price Performance
Historical ComparisonAbout TJX TJX Companies Inc. (The)
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.